BIOMAT Database Logo BIOMAT Database Logo

Thalidomide maintenance in multiple myeloma: certainties and controversies. 2009

Michele Cavo, and Lucia Pantani, and Paola Tacchetti, and Maria Caterina Pallotti, and Annamaria Brioli, and Alessandro Petrucci, and Elena Zamagni, and Patrizia Tosi

UI MeSH Term Description Entries
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D013792 Thalidomide A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. Sedoval,Thalomid
D014182 Transplantation, Autologous Transplantation of an individual's own tissue from one site to another site. Autografting,Autologous Transplantation,Autotransplantation,Autograftings,Autologous Transplantations,Autotransplantations,Transplantations, Autologous
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses

Related Publications

Michele Cavo, and Lucia Pantani, and Paola Tacchetti, and Maria Caterina Pallotti, and Annamaria Brioli, and Alessandro Petrucci, and Elena Zamagni, and Patrizia Tosi
Hematology: Thalidomide maintenance in multiple myeloma.
October 2009, Nature reviews. Clinical oncology,
Michele Cavo, and Lucia Pantani, and Paola Tacchetti, and Maria Caterina Pallotti, and Annamaria Brioli, and Alessandro Petrucci, and Elena Zamagni, and Patrizia Tosi
First line vs delayed transplantation in myeloma: Certainties and controversies.
June 2016, World journal of transplantation,
Michele Cavo, and Lucia Pantani, and Paola Tacchetti, and Maria Caterina Pallotti, and Annamaria Brioli, and Alessandro Petrucci, and Elena Zamagni, and Patrizia Tosi
Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis.
August 2012, Leukemia research,
Michele Cavo, and Lucia Pantani, and Paola Tacchetti, and Maria Caterina Pallotti, and Annamaria Brioli, and Alessandro Petrucci, and Elena Zamagni, and Patrizia Tosi
Maintenance therapy for multiple myeloma with particular emphasis on thalidomide.
December 2006, Onkologie,
Michele Cavo, and Lucia Pantani, and Paola Tacchetti, and Maria Caterina Pallotti, and Annamaria Brioli, and Alessandro Petrucci, and Elena Zamagni, and Patrizia Tosi
Does maintenance therapy with thalidomide benefit patients with multiple myeloma?
July 2007, Nature clinical practice. Oncology,
Michele Cavo, and Lucia Pantani, and Paola Tacchetti, and Maria Caterina Pallotti, and Annamaria Brioli, and Alessandro Petrucci, and Elena Zamagni, and Patrizia Tosi
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
November 2006, Blood,
Michele Cavo, and Lucia Pantani, and Paola Tacchetti, and Maria Caterina Pallotti, and Annamaria Brioli, and Alessandro Petrucci, and Elena Zamagni, and Patrizia Tosi
Thalidomide in multiple myeloma.
May 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Michele Cavo, and Lucia Pantani, and Paola Tacchetti, and Maria Caterina Pallotti, and Annamaria Brioli, and Alessandro Petrucci, and Elena Zamagni, and Patrizia Tosi
Thalidomide in multiple myeloma.
December 2006, Current pharmaceutical biotechnology,
Michele Cavo, and Lucia Pantani, and Paola Tacchetti, and Maria Caterina Pallotti, and Annamaria Brioli, and Alessandro Petrucci, and Elena Zamagni, and Patrizia Tosi
Thalidomide in multiple myeloma.
February 2006, Expert opinion on pharmacotherapy,
Michele Cavo, and Lucia Pantani, and Paola Tacchetti, and Maria Caterina Pallotti, and Annamaria Brioli, and Alessandro Petrucci, and Elena Zamagni, and Patrizia Tosi
Thalidomide in multiple myeloma.
March 2000, The New England journal of medicine,
Copied contents to your clipboard!